Evidence map›Paper›PMID 39958436›Full record

ArticleOrthopedic research and reviews2025

Network Pharmacology and Experimental Validation of the Therapeutic Effect of Baji Capsule on LPS-Induced Osteoporosis.

Qian Li, Dinglin Li, Ciqiu Tian, Xiangjie Liu, Hui Wang, Hao Liu

Abstract read
In one paragraph

Article in Orthopedic research and reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Integrative metabolomics and network pharmacology reveal the antifibrotic mechanisms of Gurigumu-13 in a rat model of hepatic fibrosis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Qian LiLiyuan Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Tongji Medical College of Science and Technology, Wuhan, People's Republic of China.
Dinglin LiLiyuan Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Tongji Medical College of Science and Technology, Wuhan, People's Republic of China.
Ciqiu TianHubei University of Chinese Medicine, Wuhan, People's Republic of China.
Xiangjie LiuLiyuan Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Tongji Medical College of Science and Technology, Wuhan, People's Republic of China.
Hui WangLiyuan Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Tongji Medical College of Science and Technology, Wuhan, People's Republic of China.
Hao LiuLiyuan Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Tongji Medical College of Science and Technology, Wuhan, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Osteoporosis is a common skeletal disease characterized by impaired bone microarchitecture, decreased bone mineral density and increased bone fragility, leading to a heavy physical and economic burden due to its greatly increased risk of fracture. Baji capsule is a proprietary medicine that can treat menstrual disorders and postmenopausal osteoporosis. However, the efficacy of Baji capsule has not been reported for osteoporosis caused by oxidative stress and inflammation. Therefore, the aim of this study was to evaluate whether Baji capsule has a therapeutic effect on lipopolysaccharide (LPS)-induced inflammatory osteoporosis and to explore the underlying mechanisms through network pharmacology. Patients and Methods: Osteoporosis model in ICR mice induced with LPS. Mice were treated with vitamin E (100mg/kg), PBS, high-dose Baji capsule (810mg/kg) and low-dose Baji capsule (90mg/kg), respectively. The therapeutic effect of Baji capsule was evaluated by high-resolution micro-computed tomography (Micro-CT) and tissue section staining, serum inflammatory factor levels were assessed by ELISA, serum oxidative stress-related marker levels were determined by kits, and finally the mechanism was explored by network pharmacology and then verified by immunohistochemistry. Results: Micro-CT results showed that Baji capsule attenuated LPS-induced inflammatory bone loss.Baji capsule also reduced serum inflammatory factor levels and oxygen free radical production. Target screening by network pharmacology yielded a total of 236 active ingredients of Baji capsule, as well as 278 common targets after taking the intersection of Baji capsule active ingredient targets and osteoporosis disease-related targets. Conclusion: Baji capsule can treat osteoporosis by reducing inflammation and oxidative stress. The therapeutic effects of Baji capsule were shown to be multi-targeted and multi-pathway through network pharmacology. In the future, its anti-inflammatory and antioxidant properties can be utilized to further explore its therapeutic effects on inflammatory diseases, as well as a prospective study for the clinical treatment of osteoporosis.

Indexed as

inflammatorynetwork pharmacologyosteoporosisoxidative stresstraditional Chinese medicine

Identifiers

PMID39958436
PMCPMC11829595

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.